Granulocyte-colony stimulating factor use in alcohol-associated hepatitis: is it time to promote liver regeneration?

References

• Bataller R, Arab JP, Shah VH, Hardin CC. Alcohol-associated hepatitis. N Engl J Med. 2022 Dec 29;387:2436–48. doi:10.1056/NEJMra2207599.
   PubMed Web of Science ®Google Scholar
• Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, Downs N, Gleeson D, MacGilchrist A, Grant A, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015 Apr 23;372:1619–28. doi:10.1056/NEJMoa1412278.
   PubMed Web of Science ®Google Scholar
• Arab JP, Díaz LA, Baeza N, Idalsoaga F, Fuentes-López E, Arnold J, Ramírez CA, Morales-Arraez D, Ventura-Cots M, Alvarado-Tapias E, et al. Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: a worldwide study. J Hepatol. 2021 Nov;75:1026–33. doi:10.1016/j.jhep.2021.06.019.
   PubMed Web of Science ®Google Scholar
• Ayares G, Idalsoaga F, Díaz LA, Arnold J, Arab JP. Current medical treatment for alcohol-associated liver disease. J Clin Exp Hepatol [Internet]. 2022 Feb 12;12:1333–48. https://www.sciencedirect.com/science/article/pii/S0973688322000226.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address: [email protected], European Association for the study of the liver. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol. 2018 Jul;69:154–81. doi:10.1016/j.jhep.2018.03.018.
   PubMed Web of Science ®Google Scholar
• Arab JP, Roblero JP, Altamirano J, Bessone F, Chaves Araujo R, Higuera-De la Tijera F, Restrepo JC, Torre A, Urzua A, Simonetto DA, et al. Alcohol-related liver disease: clinical practice guidelines by the Latin American Association for the study of the liver (ALEH). Ann Hepatol. 2019 May;18:518–35. doi:10.1016/j.aohep.2019.04.005.
   PubMed Web of Science ®Google Scholar
• Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the study of liver diseases. Hepatology. 2020 Jan;71:306–33. doi:10.1002/hep.30866.
   PubMed Web of Science ®Google Scholar
• Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, Dharancy S, Texier F, Hollebecque A, Serfaty L, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007 Jun;45:1348–54. doi:10.1002/hep.21607.
   PubMed Web of Science ®Google Scholar
• Garcia-Saenz-de-Sicilia M, Duvoor C, Altamirano J, Chavez-Araujo R, Prado V, de Lourdes Candolo-Martinelli A, Holanda-Almeida P, Becerra-Martins-de-Oliveira B, Fernandez-de-Almeida S, Bataller R, et al. A day-4 lille model predicts response to corticosteroids and mortality in severe alcoholic hepatitis. Am J Gastroenterol. 2017 Feb;112:306–15. doi:10.1038/ajg.2016.539.
   PubMed Web of Science ®Google Scholar
• Louvet A, Labreuche J, Dao T, Thévenot T, Oberti F, Bureau C, Paupard T, Nguyen-Khac E, Minello A, Bernard-Chabert B, et al. Effect of prophylactic antibiotics on mortality in severe alcohol-related hepatitis: a randomized clinical trial. JAMA. 2023 May 9;329:1558–66. doi:10.1001/jama.2023.4902.
   PubMed Web of Science ®Google Scholar
• Moreau R, Rautou PE. Editorial: G-CSF therapy for severe alcoholic hepatitis: targeting liver regeneration or neutrophil function? Am J Gastroenterol. 2014 Sep;109:1424–26. doi:10.1038/ajg.2014.250.
   PubMed Web of Science ®Google Scholar
• Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, Castel H, Duhamel A, Pageaux G-P, Leroy V, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011 Nov 10;365:1790–800. doi:10.1056/NEJMoa1105703.
   PubMed Web of Science ®Google Scholar
• Lee BP, Terrault NA. Liver transplantation for alcohol-associated liver disease: a call for national standards of best practices to monitor and bridge disparities in access and outcomes. Am J Transplant. 2023 Aug;23:1097–101.
   PubMed Web of Science ®Google Scholar
• Arab JP, Izzy M, Leggio L, Bataller R, Shah VH. Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation. Nat Rev Gastroenterol Hepatol. 2022 Jan;19:45–59. doi:10.1038/s41575-021-00527-0.
   PubMed Web of Science ®Google Scholar
• Theocharis SE, Agapitos EB, Margeli AP, Goutas ND, Kittas CN, Davaris PS. Effect of two forms of granulocyte-colony-stimulating factor on hepatic regeneration after 70% partial hepatectomy in rats. Clin Sci. 1997 Mar;92:315–20. doi:10.1042/cs0920315.
   PubMed Web of Science ®Google Scholar
• Yannaki E, Athanasiou E, Xagorari A, Constantinou V, Batsis I, Kaloyannidis P, Proya E, Anagnostopoulos A, Fassas A. G-CSF–primed hematopoietic stem cells or G-CSF per se accelerate recovery and improve survival after liver injury, predominantly by promoting endogenous repair programs. Exp Hematol. 2005 Jan 1;33:108–19.
   PubMed Web of Science ®Google Scholar
• Spahr L, Lambert JF, Rubbia-Brandt L, Chalandon Y, Frossard JL, Giostra E, Hadengue A. Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology. 2008 Jul;48:221–29. doi:10.1002/hep.22317.
   PubMed Web of Science ®Google Scholar
• Garg V, Garg H, Khan A, Trehanpati N, Kumar A, Sharma BC, Sakhuja P, Sarin SK. Granulocyte colony–stimulating factor mobilizes CD34+ cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology. 2012 Mar;142:505–12.e1. doi:10.1053/j.gastro.2011.11.027.
   PubMed Web of Science ®Google Scholar
• Engelmann C, Herber A, Franke A, Bruns T, Reuken P, Schiefke I, Zipprich A, Zeuzem S, Goeser T, Canbay A, et al. Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: a multicenter randomized trial (GRAFT study). J Hepatol. 2021 Dec;75:1346–54. doi:10.1016/j.jhep.2021.07.033.
   PubMed Web of Science ®Google Scholar
• Tayek JA, Stolz AA, Nguyen DV, Fleischman MW, Donovan JA, Alcorn JM, Chao, Daniel C-K, Asghar A, Morgan TR, et al. A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis. EClinicalMedicine. 2022 Dec;54:101689. doi:10.1016/j.eclinm.2022.101689.
   PubMedGoogle Scholar
• Marot A, Singal AK, Moreno C, Deltenre P. Granulocyte colony-stimulating factor for alcoholic hepatitis: a systematic review and meta-analysis of randomised controlled trials. JHEP Rep. 2020 Oct;2:100139. doi:10.1016/j.jhepr.2020.100139.
   PubMedGoogle Scholar
• Morales-Arráez D, Ventura-Cots M, Altamirano J, Abraldes JG, Cruz-Lemini M, Thursz MR, Atkinson SR, Sarin SK, Kim W, Chavez-Araujo R, et al. The MELD score is superior to the maddrey discriminant function score to predict short-term mortality in alcohol-associated hepatitis: a global study. Am J Gastroenterol [Internet]. 2021 Dec 28;117:301–10. doi:10.14309/ajg.0000000000001596.
   Web of Science ®Google Scholar
• Avitabile E, Díaz A, Montironi C, Pérez-Guasch M, Gratacós-Ginès J, Hernández-Évole H, Moreira RK, Sehrawat TS, Malhi H, Olivas P, et al. Adding inflammatory markers and refining National Institute on alcohol abuse and alcoholism criteria improve diagnostic accuracy for alcohol-associated hepatitis. Clin Gastroenterol Hepatol [Internet]. 2023 Mar 31. 21. 3080–3088.e9. 10.1016/j.cgh.2023.03.023.
   PubMed Web of Science ®Google Scholar
• Louvet A, Labreuche J, Artru F, Bouthors A, Rolland B, Saffers P, Lollivier J, Lemaître E, Dharancy S, Lassailly G, et al. Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: a prospective study. Hepatology. 2017 Nov;66:1464–73. doi:10.1002/hep.29240.
   PubMed Web of Science ®Google Scholar
• Farokhnia M, Berger AL, Karoly HC, Hwa LS, Varodayan FP. The promise of neuroimmune targets for treating drug addiction and other psychiatric disorders: granulocyte-colony stimulating factor exemplification. Front Psychiatry. 2020 Mar 17;11:220. doi:10.3389/fpsyt.2020.00220.
   PubMed Web of Science ®Google Scholar
• Brady LJ, Erickson KR, Lucerne KE, Osman A, Kiraly DD, Calipari ES. Granulocyte colony-stimulating factor (G-CSF) enhances cocaine effects in the nucleus accumbens via a dopamine release-based mechanism. Psychopharmacology. 2021 Dec;238:3499–509. doi:10.1007/s00213-021-05967-9.
   PubMed Web of Science ®Google Scholar
• Diaz LA, Winder GS, Leggio L, Bajaj JS, Bataller R, Arab JP. New insights into the molecular basis of alcohol abstinence and relapse in alcohol-associated liver disease. Hepatology [Internet]. 2023 Oct 20. doi:10.1097/HEP.0000000000000645.
   PubMed Web of Science ®Google Scholar
• DiMartini AF, Leggio L, Singal AK. Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models. Lancet Gastroenterol Hepatol. 2022 Feb;7:186–95. doi:10.1016/S2468-1253(21)00191-6.
   PubMed Web of Science ®Google Scholar
• Leggio L, Mellinger JL. Alcohol use disorder in community management of chronic liver diseases. Hepatology. 2023 Mar 1;77:1006–21. doi:10.1002/hep.32531.
   PubMed Web of Science ®Google Scholar
• Idalsoaga F, Ayares G, Díaz LA, Arnold J, Ayala-Valverde M, Hudson D, Arrese M, Arab JP. Current and emerging therapies for alcohol-associated hepatitis. Liver Res. 2023 Mar 1;7:35–46.
   Google Scholar
• Díaz LA, Idalsoaga F, Fuentes-López E, Márquez-Lomas A, Ramírez CA, Roblero JP, Araujo RC, Higuera‐de‐la‐Tijera F, Toro LG, Pazmiño G, et al. Impact of public health policies on alcohol-associated liver disease in Latin America: an ecological multi-national study. Hepatology [Internet]. 2021 Jun 16;74:2478–90. doi:10.1002/hep.32016.
   PubMed Web of Science ®Google Scholar
• Ayares G, Idalsoaga F, Arnold J, Fuentes-López E, Arab JP, Díaz LA. Public health measures and prevention of alcohol-associated liver disease. J Clin Exp Hepatol [Internet]. 2022 May 31 [accessed 2022 Jun 5]. http://www.jcehepatology.com/article/S0973688322001323/abstract.
   Web of Science ®Google Scholar
• Díaz LA, Fuentes-López E, Idalsoaga F, Ayares G, Corsi O, Arnold J, Cannistra M, Vio D, Márquez-Lomas A, Ramirez-Cadiz C, et al. Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes. J Hepatol [Internet]. 2023 Nov 20. doi:10.1016/j.jhep.2023.11.006.
   Web of Science ®Google Scholar
• Duan F, Liu C, Chang C, Song S, Zhai H, Cheng J, Yang S. Granulocyte colony-stimulating factor plus pentoxifylline increases short-term survival in patients with severe alcoholic hepatitis: a network meta-analysis. Am J Drug Alcohol Abuse. 2023. doi:10.1080/00952990.2023.2266117.
   Web of Science ®Google Scholar